U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177677) titled 'A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder' on Sept. 02.
Brief Summary: This clinical trial aims to evaluate the safety and preliminary efficacy of intravenous administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs) in patients with autism spectrum disorder (ASD).
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Autism Spectrum Disorder
Intervention:
BIOLOGICAL: hBMMSC
Group 1: 0.5x10^6 cells/kg (participant's body weight) single dose; Group 2: 1.0x10^6 cells/kg (participant's body weight) single dose; Group 3: 2.0x10^6 cells/kg (participant's body weigh...